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Abstract
Background: The presence of submucous fibroids strongly impacts on IVF results, therefore, these patients should
be considered for surgical or medical treatment. The aim of this study was to assess the role of Ulipristal acetate
(UPA), a selective progesterone receptor modulator, in restoring uterine cavity deformation due to submucous
fibroids, in infertile patients attempting an IVF treatment. The secondary study outcome was to evaluate the impact
of preconception UPA treatment on rate of biochemical pregnancy, ongoing pregnancy, and live birth compared
to a control group without fibroids.
Methods: Infertile patients with submucosal fibroid (Type 1 and Type 2 according to FIGO classification) were
enrolled in the study as fibroids group and received 1 to 3 treatment cycles of UPA, according to their response, as
reflected by fibroid volume reduction and restoration of normal uterine cavity. Patients in control group were
randomly selected from a general IVF cohort by a ratio of 2:1 with fibroids group, matched by age, BMI, type and
cause of infertility and antral follicle count. The impact of UPA on fibroids volume reduction was evaluated. IVF
outcome was compared between groups.
Results: Twenty-six patients underwent UPA treatment revealed a mean volume reduction of their fibroids of 41%.
A total of 15 (57.6%) biochemical pregnancy were obtained, resulting in 13 (50%) ongoing pregnancy and 9 (34.6%)
healthy babies were already delivered. Similar results were obtained in control group.
Conclusion: Restoration of normal uterine cavity by UPA treatment prior to IVF treatment avoids surgery and
establishes a pregnancy rate comparable to a control group without fibroids.
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Background
Uterine leiomyomas, or fibroids, are the most common
form of benign uterine tumors occurring in 20–40% of
women of reproductive age [1]. They are hormone-
sensitive, smooth-muscle tumors with a wide heterogeneity
in composition, size and number [2].
In the majority of cases, fibroids are asymptomatic, the
diagnosis is incidental and need no intervention. How-
ever, third of cases represent with a variety of symptoms,
depending on their location and size, and require treat-
ment. The most common symptom is abnormal uterine
bleeding, usually excessive menstrual bleeding with sub-
sequent anemia, which could be life-threatening. Other
symptoms include pelvic pressure, bowel dysfunction,
urinary frequency and urgency, urinary retention, low
back pain, constipation, dyspareunia and obstetrics
complications [2].
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Infertility and recurrent miscarriages may also be
symptoms of fibroids. Their anatomical location, specif-
ically submucous and intramural fibroids, seems to be
the most relevant factor affecting fertility and fertility
treatments [1, 3, 4].
Fibroids can impair fertility through several possible
mechanisms including: alteration of the local anatomy
(anatomic distortion of the uterine cavity) with subsequent
endometrial function modification [3]; functional changes,
such as increased uterine contractility and impairment of
the endometrial and myometrial blood supply [1]; and
changes to the local hormone milieu which could impair
gamete transport and/or reduce blastocyst implantation
[5]. The type of treatment is guided by fibroid’s characteris-
tics (size, number and location), patient’s age and whether
the women desires to preserve fertility or not.
Submucous fibroids (Type 1 and 2 according to FIGO
leiomyoma sub-classification system) [6] distorting the
uterine cavity, negatively impact implantation rates, preg-
nancy outcomes and IVF treatments success [1, 3, 4, 7, 8].
Therefore, before starting IVF procedure, the resection of
submucosus fibroids is strongly recommended [9]. Treat-
ment of fibroids is mainly surgical and the gold standard
for submucosal fibroids is hysteroscopic myomectomy, en-
hancing conception and live births with a pregnancy rate in
infertile women ranging from 16 to 76.9% [1, 7, 9, 10].
Beside the surgical eradication, several medical therap-
ies are now available. One of which is Ulipristal acetate
(UPA), a selective progesterone receptor modulator
(SPRM). UPA is effective in controlling excessive bleed-
ing, reducing fibroids volume and has been proposed as
a pre-operative treatment in those women with symp-
tomatic myomas undergoing surgical therapy [11, 12].
Data on pregnancy achievement after UPA treatment
are inconsistent and mainly based on case reports and
small series, but it seems to enhance the chance of
conception [13, 14].
Luyckx et al. report the first series of pregnancies
achieved after UPA treatment, with a pregnancy rate of
71% in the group of patients wishing to conceive. They
also describe pregnancies obtained after UPA treatment
for fibroids in women who did not undergo surgery [14];
however only two patients conceived without surgery
and this contributes to the weakness of the published
results. Recently, the first case of infertile advance-age
patient with large intramural fibroid, who conceived by
IVF treatment following a course of Ulipristal was re-
ported [15]. The patient underwent two fresh fertility
preserving IVF cycles, with cryopreservation of 9 day-3
embryos, followed by a 12 weeks course of UPA (5 mg
per day) and a subsequent frozen-thawed embryo trans-
fer with her own previously cryopreserved embryos.
Prompted by the aforementioned information we
aimed to evaluate the efficacy of UPA in avoiding
surgery and restoring uterine cavity deformation due to
submucous fibroids, in infertile patients attempting an
IVF treatment. The secondary outcome was to evaluate
the impact of pre-IVF UPA treatment on number of
oocyte retrieval and embryos obtained, biochemical
pregnancy rate, ongoing pregnancy rate, live birth rates,
compared to a control group without fibroids.
Materials and methods
A prospective study was conducted at “Santa Maria alle
Scotte” University Hospital, Department of Molecular
and Developmental Medicine and it was approved by
the ethical committee of the Siena University under the
ID 10818_2017 clinical protocol.
Consecutive patients with uterine fibromatosis who
underwent their first IVF cycle between March 2017 and
March 2018 were included in the study. The inclusion
criteria in the fibroids group were: age between 20 and
38 years; regular menstrual cycles of 25–35 days; basal
FSH less than 12 IU/L (cycle day 2–5); total antral fol-
licle count of 10–25 follicles; infertility resulting from
tubal factors; unexplained infertility; presence of both
ovaries; IVF cycle followed by fresh embryo transfer.
The first selection criterion in the fibroids group was
the presence of a submucosal fibroid with more than 3
cm diameter, which cannot be treated with one step hys-
teroscopic approach [9]. Only those classified as Type 1
to Type 2, according to the FIGO classification [6] and
distorting the uterine cavity were included.
The exclusion criteria were: obesity (patient BMI > 30
Kg/m2); more than 2 fibroids; history of myomectomy;
endometrial lesions (polyps, endometrial hyperplasia, and
intrauterine adhesions); uterine malformations (septum,
unicornuate or bicornuate uterus); sonographic features of
endometriosis and/or adenomyosis; previous surgery for
endometriosis; history of pelvic inflammatory disease;
polycystic ovarian syndrome; previous surgery for inferti-
lity; chromosomal abnormality of male or female partner.
Other major comorbidities such as diabetes, hyperten-
sion, bowel chronic diseases, rheumatologic diseases or
male infertility were also considered as exclusion criteria.
All medical conditions (including obesity) that can inter-
fere with the female fertility rate have been excluded, in
order to eliminate these possible confusing factors. Only
female fertility was considered.
In an attempt to demonstrate that women with sub-
mucosal myomas, following treatment with Esmya be-
fore IVF, achieved fibroid regression and restoration of
the uterine cavity, as reflected by their success rate dur-
ing IVF, we chose to compared them to healthy women
without fibroids. This control group included women
with normal uterus that underwent IVF treatment dur-
ing the same period and were randomly selected from
the same database, matched by age, type of infertility
Morgante et al. Reproductive Biology and Endocrinology           (2020) 18:50 Page 2 of 8
(primary and secondary), cause of infertility (Tubal,
Ovarian or Unexplained factors), and antral follicle
count, in a ratio of 2:1 with fibroids group. The same
selection criteria used for UPA treatment selection were
applied to the control group.
All the women of the fibroid group underwent pre-
treatment transvaginal ultrasound in which the size of
fibroids (the three major diameters) were recorded and a
sonohysterography to assess the cavity distortion was
performed. After confirming the diagnosis, UPA tablets
5 mg (Esmya, Gedeon Richter, Italy) was prescribed and
the patients started therapy at the beginning of the next
menstrual cycle. Each patient was asked to take UPA at
the dose of one tablet every day for 84 days (first cycle of
treatment) up to 3 cycle of treatment, with a full men-
strual cycle wash-out between two consecutive cycles; a
blood sample was collected monthly to evaluate the liver
enzymes profile and test UPA toxicity. This treatment
and management are part of our standard clinical
practice.
Follow-up visits were carried out at the end of every
cycle of UPA therapy: fibroids size was measured by
transvaginal ultrasound and a sonohysterography was
repeated. A normal uterine cavity with no remaining
myomas submucosal portion at sonohysterography was
considered the condition allowing to proceed to ART;
otherwise, only if a reduction of the volume was de-
tected, an additional UPA cycle was proposed to the pa-
tient. In case of no change in fibroid volume the patient
was withdrawn from the study and referred to surgery.
The time lapse between Ulipristal therapy and IVF
treatment was a menstrual cycle. Menses were synchro-
nized with combined oral contraception pills and ovar-
ian hyperstimulation was carried out from the second
day of the menstruation with a standard start dose of
225 IU of urofollitrophin hormone (uFSH).
The dose was adjusted based on follicle measurements
and hormonal evaluation of estradiol (E2) and progester-
one (P) at the first ultrasound examination on day 6 of the
cycle and subsequently every 2–3 days. When follicles
reached a mean diameter of 14mm, GnRH antagonist was
started and continued throughout the stimulation period.
Once at least one follicle reached a diameter of
> 18 mm and two additional follicles reached a diameter
of > 16mm, 250 mcg of r-hCG (Ovitrelle; Merck Serono,
Germany) was administered to trigger ovulation, and
34–36 h later oocytes were retrieved.
A maximum of two cleaved-embryos or blastocysts
were transferred 2–5 days after oocyte retrieval.
Vaginal capsules of micronized 200 mg progesterone
(three times/day) were administered from the day of
oocyte retrieval and continued for at least 14 days after
embryo transfer. This ART procedure refer to both
control and fibroid group.
Biochemical pregnancy was defined as transiently posi-
tive β-hCG level not associated with the development of
an embryo, while ongoing pregnancy was referred as a
viable intrauterine pregnancy of at least 12 weeks
duration confirmed on ultrasound scan.
Medical history of all women was collected from our
electronic database and data about previous pregnancy
or surgery, ovarian stimulation, oocyte retrieval and
ART details were recorded.
Plasma concentration of FSH and AMH were measured
using Access Immunoassay System (Beckman Coulter,
Milan, Italy); for progesterone and estradiol were used
Immunolite 2000 system Kits (Siemens, Los Angeles, CA,
USA). The samples were analysed twice with two dilu-
tions. For each test, controls at low, medium and high
concentration were included. The dosing limits were 0,1
ng/ml for progesterone, 15 pg/ml for estradiol, 0,2 mUI/
ml for FSH and AMH. Plasma liver enzymes was deter-
mined by an enzymatic assay (Bristol, Paris, France). The
methods used are highly specific for each hormone and
have low cross-reactivity (b.0.5%) with other hormones or
drugs present in the samples.
Statistical analysis
The Student’s t-test was used to compare means of the
two groups for normally distributed continuous variables,
and paired sample t-test was performed. The Mann-
Whitney U test was used when continuous variables did
not follow a normal distribution. The chi-squared test or
Fisher’s exact test, where appropriate, were used for com-
parisons of categorical variables. The data are presented as
mean, standard deviation (SD) or as percentages. Statis-
tical significance was set at a p value < 0.05. All statistical
analyses were performed using the Graph Pad Prism 6
software.
Results
During the study period a total of 40 patients with infer-
tility and a diagnosis of submucosal fibroid (Type 1 and
Type 2) were referred to our fertility clinic, of whom 27
were eligible and therefore enrolled in the study as fi-
broids group and received 1 to 3 cycle of UPA treatment,
accordingly to the volume reduction and the effect of
the fibroid on the uterine cavity. Patients’ characteristics
are showed in Table 1.
Mean patients’ age was 33,7 years (range 30–36). The
mean number of fibroids per patient was 1.4; 15 patients
had one fibroid while 12 had 2 fibroids (Table 1). The
mean diameter of the fibroids distorting the cavity was
5.5 cm (ranging from 3.7 to 6.3 cm).
The patients received a mean of 1.8 UPA treatment
cycles leading to a mean 41% ± 13.37 reduction in the
fibroid volume (range 16 to 68%) (Fig. 1). The volume
before treatment was 399.17 ± 285.20 cm3 and become
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257.02 ± 203.83 cm3 after UPA cycles. The volume of
myoma nodule was calculated as 1/6 π × L1 × L2 × L3
where L1, L2, and L3 are the three diameters of the
nodule that are at right angles to each other. Only one
patient did not respond to UPA treatment and showed a
volume augmentation of 9.2% and was therefore ex-
cluded from the study and referred to surgery after the
first 3-month UPA treatment cycle.
Biochemical parameters are reported in Table 2: after
UPA treatment patients showed a significant improvement
in hemoglobin and hematocrit Follicle-stimulating
hormone (FSH) values significantly increased, with no
changes in anti-mullerian hormone (AMH) values. No dif-
ferences are recorded between fibroids group after UPA
treatment and the control group (Table 2). Amongst the 26
patients who underwent ovarian stimulation for IVF, a
mean of 4.4 (2–7) oocyte per patient were collected; 3.4 (1–
5) embryos were obtained and a maximum of 2 embryos
were transferred. A total of 15 (57.6%) biochemical preg-
nancy were obtained resulting in 13 (50%) ongoing preg-
nancy and 9 (34.6%) healthy babies were already delivered.
No cases of fetal malformation, stillbirth or neonatal death
Table 1 Patients’ characteristics: anthropometric data, parity and number of UPA cycles have been reported
Patients’ characteristics Fibroids group (N 27) Control group (N 54) P value
Age (years) 33.72 ± 1.77 33.83 ± 0.39 ns
Body mass index (Kg/m2) 23.44 ± 1.86 23.67 ± 0.25 ns
Nulliparous 20 (74)a 38 (70)a ns
Primiparous 7 (26)a 16 (30)a ns
Previous miscarriage 14 (52)a 25 (46.3)a ns
Number UPA cycle 1.8 ± 0.58 Na
Patients with one fibroid 15 (55)a Na
Patients with two fibroids 12 (45)a Na
Data are expressed as Mean ± Standard Deviation
Na not applicable, Ns not significant
aData are expressed as absolute number (percentage)
Fig. 1 Individual differences in fibroids volume before and after UPA treatment. UPA treatment led to a mean reduction in volume of the myoma
impacting the cavity of 41% ± 13.37. The volume before treatment was 399.17 ± 285.20 ml and become 257.02 ± 203.83 after UPA cycles. The
volume of myoma nodule was calculated as 1/6 π × L1 × L2 × L3 where L1, L2, and L3 are the three diameters of the nodule that are at right
angles to each other. Individual differences in fibroids volume after treatment and the percentage of volume reduction for each patients were
reported. The percentage of reduction was always significant. Only one patient did not respond to UPA treatment and showed a volume
augmentation of 9.2%
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were recorded. When compared with the control group the
same results were obtained (Table 3).
Within the fibroids group, no differences in the
amount of volume fibroids reduction were observed be-
tween patients who conceived, had biochemical/ultra-
sound diagnosis of pregnancy or childbirth, and those
who did not (Table 4). No adverse effects or liver en-
zymes alteration were recorded during the study period
(Table 2).
Discussion
Our study shows that restoration of normal uterine cav-
ity prior to IVF treatment by UPA therapy may avoid
surgery and establishes a pregnancy rate comparable to
a control group without fibroids. The role of progester-
one and its receptors has been extensively studied during
the last years as being decisive in promoting the growth
of uterine fibroids and has stimulated interest in modu-
lating the progesterone pathways [16].
Selective progesterone receptor modulators (SPRMs)
are drugs that exert agonistic or antagonistic effect on
progesterone receptors and can modulate progesterone
effect on different tissues [17]. UPA is a SPRM that
block progestogen activity and is effective in reducing
uterine fibroids volume. This effect lasts over time, with-
out major side effects [17]. In line with previous publica-
tions, in our series there was a mean volume reduction
of 41% and only one patient was referred to surgery
because no fibroid size reduction was detected.
The advantages of UPA are rapid reduction of amount
of bleeding in most cases and a significant reduction in
fibroid volume [9]. Christopoulos et al. demonstrated
that the presence of fibroids not distorting uterine cavity
negatively affect clinical pregnancy (odds ratio, OR 0.62;
95% confidence interval, 95% CI 0.41–0.94) and live
Table 2 Patients’ biochemical parameters: hormonal and hemoglobin values have been reported. The liver enzyme profile was also
analyzed to assess UPA toxicity
Patients’ biochemical parameters Fibroids group “before UPA” Fibroids group “after UPA” Control group P value
FSH (mUI/ml) 9.83 ± 1.14 10.04 ± 1.26 10.24 ± 0.23 0.0034a
nsb
AMH (mUI/ml) 1.15 ± 0.26 1.11 ± 0.23 1.16 ± 0.05 nsa
nsb
Hb (g/dl) 11.06 ± 0.66 11.51 ± 0.50 11.76 ± 0.12 0.0001a
nsb
Hct (%) 36.58 ± 1.47 37.11 ± 1.19 37.27 ± 0.20 0.0027a
nsb
GOT (UI/l) 16.45 ± 0.76 17.01 ± 0.56 17.59 ± 0.66 nsa
nsb
GPT (UI/l) 12.16 ± 0.45 13.58 ± 0.55 13.34 ± 0.75 nsa
nsb
Gamma glutamyl transferase (UI/l) 5.21 ± 0.15 6.01 ± 0.19 5.65 ± 0.23 nsa
nsb
Alkaline Phosphatase (UI/l) 43.41 ± 1.25 44.13 ± 1.05 44.21 ± 0.78 nsa
nsb
Data are expressed as Mean ± Standard Deviation
FSH follicle-stimulating hormone, AMH anti-mullerian hormone, Hb hemoglobin, Hct hematocrit, Ns not significant
abetween fibroids group before and after UPA treatment
bbetween fibroids group after UPA and control group
Table 3 IVF and neonatal outcomes
IVF outcomes Fibroids group (N 26) Control group (N 54) P value
Oocyte retrieval 4.44 ± 1.29 4.27 ± 0.27 ns
Number Embryos obtained 3.44 ± 1.20 3.27 ± 0.23 ns
Biochemical pregnancy 15 (57.6)a 33 (61.1)a ns
Ongoing pregnancy 13 (50)a 27 (50)a ns
Healthy babies delivered 9 (34.6)a 20 (37)a ns
Data are expressed as Mean ± Standard Deviation
Ns not significant
aData are expressed as absolute number (percentage)
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birth rates (OR 0.58; 95% CI 0.48–0.78) in patients
undergoing their first IVF/ICSI cycle [18]. The presence
of submucous fibroids strongly impacts on IVF results,
therefore, this patient should be considered for surgical
or medical treatment [4]. Data on UPA exposure before
IVF is limited, except for some case reports focused on
intramural fibroids [15, 18, 19]. Wdowiack et al. re-
ported a case of pre-treatment with UPA before an ICSI
procedure ending with conception and vaginal delivery
of a baby [19]. Lo Monte et al. report a case of multiple
uterine fibroids with two fibroids distorting the uterine
cavity, who were treated with 3months UPA prior to
hysteroscopic myomectomy and followed for three more
months. Nine months after a second cycle of UPA the
patient underwent an IVF treatment [20]. Moreover,
since the major disadvantage of myomectomy is the
need for an optimal waiting period between surgery and
subsequent fertility treatment [21].
Orvieto et al. has suggested that while counselling an
advance-age patient with prominent intramural fibroid,
the treatment of choice should be 1–3 IVF cycles, aim-
ing to cryopreserve 5–10 embryos, followed by a 12
weeks course of Ulipristal and a subsequent FET with
her own previously cryopreserved embryos [15].
Our study have some limitations. The high success rate
recorded in our sample, concerning the restoration of
uterine cavity can be explained by the following factors:
low number of patients, young age, and obesity as an ex-
clusion factor. These features could improve response to
therapy and may have limited the generalizability of our
findings. Moreover, our healthy control group was chosen
in an attempt to demonstrate that women with submuco-
sal myomas, when treated with Esmya before IVF,
achieved IVF success rate comparable to healthy women
without fibroids. An ideal control would be women with
previous myomectomy undergoing IVF, which unfortu-
nately we could not achieve.
The present study is the first case-series, where UPA
has been used in patient with fibroids distorting the
uterine cavity prior to IVF treatment, demonstrating an
ongoing pregnancy rate of 50%, comparable to that ob-
tained in patients without fibroids. No differences in the
amount of volume fibroids reduction were observed be-
tween patients who conceived and those who did not.
Getting pregnant is the result of multiple factors, not only
mechanical, but also hormonal, endometrial, vascular and
inflammatory. UPA treatment is important not only be-
cause it reduces the size of the fibroids and their impact
on the uterine cavity but allows to reduce the inflamma-
tory state associated with these lesions. On the one hand
restoring the correct anatomy of the uterus, and on the
other hand reducing the inflammatory state are funda-
mental goals for achieving pregnancy in these women.
Furthermore, we didn’t observe any complication dur-
ing pregnancy, related to excessive growth of the fibroid.
Apoptosis and the sustained decrease in myoma size
seen after UPA treatment could explain the absence of
regrowth during pregnancy, despite high levels of
circulating progesterone [14].
Indeed, in the case of pregnancy the presence of
myomas -in particular of myomas that distort the uter-
ine cavity and larger intramural myomas- has been
linked to an increased risk of spontaneous abortion,
fetal malpresentation, placenta previa, preterm birth,
cesarean section, and peripartum hemorrhage [22].
Clinical experience and observational studies suggest
that fibroid treatment may improve the outcome of
pregnancy [22, 23].
Pre ART UPA treatment does not impair embryos
quality or foetal morphology and the subsequent
pregnancy did not affect fibroid size [19].
As described by Donnez in 2016, in case of fibroids
greater than 3 cm, a preoperative treatment is advisable
[9]. Pre-surgical UPA treatment for large and complex
fibroid induces its shrinkage and increases the rate of
complete resection with a shorter surgical procedure,
allowing the possibility of one-time hysteroscopic resec-
tion [23, 24].
Table 4 Within the fibroids group, characteristics relating to fibroids are reported. Fibroids volume reduction after UPA treatment
was compared between patients who conceived and those who did not
Patients who conceived Patients who did not conceived P value
Number of UPA cycle 1.9 ± 0.51 1.7 ± 0.61 ns
Number of fibroids 1.36 ± 0.50 1.54 ± 0.52 ns
Fibroids Localization
-anterior 42% 36% ns
-posterior 38% 41% ns
-lateral 20% 23% ns
% of fibroids volume reduction 41.4 ± 12.44 39.51 ± 14.48 ns
Data are expressed as Mean ± Standard Deviation
Ns not significant, UPA Ulipristal acetate
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Our case-series suggest the pre-ART UPA treatment, as a
possible alternative to surgery, with a reasonable pregnancy
rate and avoiding possible surgical complications [25].
In conclusion, the presence of submucous fibroids
strongly impacts on IVF results, therefore, this patient
should be considered for surgical or medical treatment.
UPA therapy is efficient in restoring uterine cavity de-
formation and improving subsequent IVF outcome.
Avoiding surgery is also crucial in infertile women. Fur-
ther large randomized controlled studies are needed to
confirm our observation and to further define patient
selection criteria. These will aid both fertility specialists’
counselling and their patients in tailoring the correct
approach to submucosal fibroid, optimizing the results
without losing time.
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